Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 122.85% | 14.68% | 46.34% | 52.35% | 57.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 122.85% | 14.68% | 46.34% | 52.35% | 57.64% |
| Cost of Revenue | 205.51% | 14.70% | 520.51% | 1.87% | -9.90% |
| Gross Profit | 107.47% | 14.67% | -143.39% | 69.51% | 83.17% |
| SG&A Expenses | 16.22% | 14.48% | 71.68% | 60.11% | 67.00% |
| Depreciation & Amortization | -1.95% | 0.01% | 0.87% | -0.96% | 0.24% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.19% | 11.03% | 192.93% | 30.73% | 28.03% |
| Operating Income | 393.82% | 31.51% | -1,326.87% | 150.24% | 1,044.72% |
| Income Before Tax | 2,326.49% | 117.16% | -144.23% | -329.28% | 47.80% |
| Income Tax Expenses | 2,764.83% | 147.30% | -128.30% | -643.54% | 144.52% |
| Earnings from Continuing Operations | 1,735.15% | 109.34% | -149.28% | -270.93% | 30.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,735.15% | 109.34% | -149.28% | -270.93% | 30.19% |
| EBIT | 393.82% | 31.51% | -1,326.87% | 150.24% | 1,044.72% |
| EBITDA | 217.08% | 9.67% | -341.22% | 85.57% | 92.15% |
| EPS Basic | 1,638.26% | 108.71% | -145.54% | -257.35% | 34.12% |
| Normalized Basic EPS | 1,045.41% | 38.70% | -1,405.94% | 572.69% | -398.71% |
| EPS Diluted | 1,556.41% | 108.33% | -146.57% | -259.09% | 34.02% |
| Normalized Diluted EPS | 997.22% | 34.53% | -1,434.24% | 580.31% | -398.71% |
| Average Basic Shares Outstanding | 6.29% | 7.21% | 8.23% | 8.63% | 5.98% |
| Average Diluted Shares Outstanding | 12.00% | 10.53% | 5.90% | 7.34% | 5.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |